StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
May 31, 2019 6:48 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Merck (MRK), AstraZeneca (AZN) Report Results from Phase 3 POLO trial evaluating LYNPARZA as First-Line Maintenance Therapy
June 3, 2019 6:04 AM
Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase
May 31, 2019 6:45 AM
